VIR Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of -73950.52% compared to Vir Biotechnology's net margin of 14.23%. Vir Biotechnology's return on equity of -35.62% beat Biomarin Pharmaceutical's return on equity of 6.29%.

Vir Biotechnology has a consensus price target of $31.25, signalling upside risk potential of 298.65%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $98.08 which suggests that it could grow by 46.34%. Given that Vir Biotechnology has higher upside potential than Biomarin Pharmaceutical, analysts believe Vir Biotechnology is more attractive than Biomarin Pharmaceutical.

Vir Biotechnology has a beta of 0.492, which suggesting that the stock is 50.783% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.295, suggesting its less volatile than the S&P 500 by 70.544%.

Vir Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vir Biotechnology pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Vir Biotechnology quarterly revenues are $289K, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.7M. Vir Biotechnology's net income of -$213.7M is lower than Biomarin Pharmaceutical's net income of $106.1M. Notably, Vir Biotechnology's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 40.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vir Biotechnology is 16.19x versus 4.78x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

FibroGen has a net margin of -73950.52% compared to Vir Biotechnology's net margin of -36.87%. Vir Biotechnology's return on equity of -35.62% beat FibroGen's return on equity of --.

Vir Biotechnology has a consensus price target of $31.25, signalling upside risk potential of 298.65%. On the other hand FibroGen has an analysts' consensus of $10.00 which suggests that it could grow by 1627.12%. Given that FibroGen has higher upside potential than Vir Biotechnology, analysts believe FibroGen is more attractive than Vir Biotechnology.

Vir Biotechnology has a beta of 0.492, which suggesting that the stock is 50.783% less volatile than S&P 500. In comparison FibroGen has a beta of 0.823, suggesting its less volatile than the S&P 500 by 17.658%.

Vir Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FibroGen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vir Biotechnology pays -- of its earnings as a dividend. FibroGen pays out -- of its earnings as a dividend.

Vir Biotechnology quarterly revenues are $289K, which are smaller than FibroGen quarterly revenues of $46.3M. Vir Biotechnology's net income of -$213.7M is lower than FibroGen's net income of -$17.1M. Notably, Vir Biotechnology's price-to-earnings ratio is -- while FibroGen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vir Biotechnology is 16.19x versus 0.32x for FibroGen. Usually stocks with elevated PS ratios are considered overvalued.

GlycoMimetics has a net margin of -73950.52% compared to Vir Biotechnology's net margin of --. Vir Biotechnology's return on equity of -35.62% beat GlycoMimetics's return on equity of --.

Vir Biotechnology has a consensus price target of $31.25, signalling upside risk potential of 298.65%. On the other hand GlycoMimetics has an analysts' consensus of -- which suggests that it could grow by 291.54%. Given that Vir Biotechnology has higher upside potential than GlycoMimetics, analysts believe Vir Biotechnology is more attractive than GlycoMimetics.

Vir Biotechnology has a beta of 0.492, which suggesting that the stock is 50.783% less volatile than S&P 500. In comparison GlycoMimetics has a beta of 1.771, suggesting its more volatile than the S&P 500 by 77.069%.

Vir Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GlycoMimetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vir Biotechnology pays -- of its earnings as a dividend. GlycoMimetics pays out -- of its earnings as a dividend.

Vir Biotechnology quarterly revenues are $289K, which are larger than GlycoMimetics quarterly revenues of --. Vir Biotechnology's net income of -$213.7M is lower than GlycoMimetics's net income of -$9.8M. Notably, Vir Biotechnology's price-to-earnings ratio is -- while GlycoMimetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vir Biotechnology is 16.19x versus -- for GlycoMimetics. Usually stocks with elevated PS ratios are considered overvalued.

Janux Therapeutics has a net margin of -73950.52% compared to Vir Biotechnology's net margin of -6391.57%. Vir Biotechnology's return on equity of -35.62% beat Janux Therapeutics's return on equity of -11.37%.

Vir Biotechnology has a consensus price target of $31.25, signalling upside risk potential of 298.65%. On the other hand Janux Therapeutics has an analysts' consensus of -- which suggests that it could grow by 66.1%. Given that Vir Biotechnology has higher upside potential than Janux Therapeutics, analysts believe Vir Biotechnology is more attractive than Janux Therapeutics.

Vir Biotechnology has a beta of 0.492, which suggesting that the stock is 50.783% less volatile than S&P 500. In comparison Janux Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Vir Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Janux Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vir Biotechnology pays -- of its earnings as a dividend. Janux Therapeutics pays out -- of its earnings as a dividend.

Vir Biotechnology quarterly revenues are $289K, which are smaller than Janux Therapeutics quarterly revenues of $439K. Vir Biotechnology's net income of -$213.7M is lower than Janux Therapeutics's net income of -$28.1M. Notably, Vir Biotechnology's price-to-earnings ratio is -- while Janux Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vir Biotechnology is 16.19x versus 216.51x for Janux Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.